[1] Liu W, Liu Song Y, Wang X. Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019[J] Aging (Albany NY). 2022 ,14(7):3175-3190. [2] Tilly H, Morschhauser F, Sehn L H, et al.Polatuzumabvedotin in previously untreated diffuse large b-cell lymphoma[J] N Engl J Med, 2022,386(4):351-363. [3] Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 Bispecific T-cell-engaging antibody, in relapsed or refractory large B-Cell lymphoma: dose expansion in a phase i/ii trial[J]J Clin Oncol,2023,41(12):2238-2247. [4] Yagi Y, Kanemasa Y, Sasaki Y, et al. Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: a retrospective study[J]Cancer Med,2023,12(17):17808-17821. [5] Freites M A,Santana N, Arias S S, et al. Using the common terminology criteria for adverse events (ctcae-version 5.0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr (Engl Ed), 2021,112(1):90-92. [6] Sawalha Y. Relapsed/refractory diffuse large B-Cell Lymphoma: a look at the approved and emerging therapies[J]. J Pers Med,2021,11(12):1345. [7] 中国临床肿瘤学会(CSCO)淋巴瘤专家委员.格菲妥单抗治疗弥漫大 B细胞淋巴瘤临床用药指导原则(2024年版)[J]. 白血病·淋巴瘤, 2024,33(5):257-264. [8] 霍文倩.脓疱疹继发传染性湿疹样皮炎1例[J].武警医学,2023,34(1):57-58. [9] 孙建芳,周自福,张 勋,等.烧伤后继发传染性湿疹样皮炎的临床特点及创面细菌学分析[J].宁夏医科大学学报,2021,43(3):299-302. [10] 孔英琪,陈 浩.新型药物的皮肤不良反应[J].中国皮肤性病学志,2021,35(5):570-575. [11] 王天竹,张昌盛.舒更葡糖钠拮抗罗库溴铵过敏1例[J].武警医学,2022,33(7):623-624.
PDF(1131 KB)
